MedPath

Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy

Phase 3
Completed
Conditions
Infection
Multiple Myeloma
Interventions
Registration Number
NCT00002850
Lead Sponsor
Gary Morrow
Brief Summary

RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy.

PURPOSE: This randomized clinical trial is studying antibiotics to see how well they work compared to no antibiotics in preventing early infection in patients with multiple myeloma.

Detailed Description

OBJECTIVES:

* Evaluate whether oral antibiotic prophylaxis with co-trimoxazole (TMP-SMX) versus ciprofloxacin (CPFX) or ofloxacin versus no prophylaxis will significantly reduce rates of serious bacterial infections during the first 3 months of chemotherapy in patients with multiple myeloma.

* Determine whether antibiotic prophylaxis with TMP-SMX or CPFX (or ofloxacin) is associated with an increased incidence of nonbacterial infection or an increased rate of infection from organisms resistant to prophylactic antibiotics.

* Evaluate whether oral antibiotic prophylaxis with CPFX or ofloxacin is as effective as TMP-SMX without the associated toxic effects.

* Evaluate whether protection against early infection in multiple myeloma patients can improve their response to initial chemotherapy.

OUTLINE: This is a randomized, multicenter study. Patients are stratified by participating center. Patients are randomized to 1 of 2treatment arms.

* Arm I: Patients receive co-trimoxazole every 12 hours for 2 months followed by observation for 2 months.

* Arm II: Patients receive oral ciprofloxacin or ofloxacin every 12 hours for 2 months followed by observation for 1 month.

* Arm III: The patient will receive no prophylaxis.

Patients continue their randomly assigned treatment throughout any infection in addition to any treatment needed for infection. Patients also remain on their randomly assigned treatment if chemotherapy is discontinued, changed, or delayed during the 3 month study.

Patients are followed at 6 months, 1 year, and 2 years.

PROJECTED ACCRUAL: A total of 212 patients (71 per treatment arm) will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
212
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TMP-SMX160 mg trimethoprim and 800 mg sulfamethoxazoleTMP-SMX: 160 mg trimethoprim and 800 mg sulfamethoxazole every 12 hours
Ciprofloxacin or ofloxacinciprofloxacinQuinolone: Ciprofloxacin 500 mg every 12 hours or Ofloxacin400 mg every 12 hours.
Ciprofloxacin or ofloxacinofloxacinQuinolone: Ciprofloxacin 500 mg every 12 hours or Ofloxacin400 mg every 12 hours.
Primary Outcome Measures
NameTimeMethod
Proportion of Patients Experiencing a Serious Bacterial InfectionFirst three months of chemotherapy

This study evaluated the impact of prophylactic antibiotics on the incidence of serious bacterial infections (SBIs) during the first 2 months of treatment in patients with newly diagnosed multiple myeloma. Patients with multiple myeloma receiving initial chemotherapy were randomized on a 1:1:1 basis to daily ciprofloxacin, trimethoprim-sulfamethoxazole, or observation and evaluated for SBI for the first 2 months of treatment.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (45)

CCOP - Columbus

๐Ÿ‡บ๐Ÿ‡ธ

Columbus, Ohio, United States

St. Mary's Hospital Medical Center - Green Bay

๐Ÿ‡บ๐Ÿ‡ธ

Green Bay, Wisconsin, United States

Siouxland Hematology-Oncology Associates, LLP

๐Ÿ‡บ๐Ÿ‡ธ

Sioux City, Iowa, United States

St. Luke's Regional Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Sioux City, Iowa, United States

CCOP - Kalamazoo

๐Ÿ‡บ๐Ÿ‡ธ

Kalamazoo, Michigan, United States

CCOP - Kansas City

๐Ÿ‡บ๐Ÿ‡ธ

Kansas City, Missouri, United States

Our Lady of Mercy Medical Center Comprehensive Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Bronx, New York, United States

Instituto Nacional de Enfermedades Neoplasicas

๐Ÿ‡ต๐Ÿ‡ช

Lima, Peru

CCOP - Dayton

๐Ÿ‡บ๐Ÿ‡ธ

Dayton, Ohio, United States

Bay Area Cancer Care Center at Bay Area Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Marinette, Wisconsin, United States

CCOP - Marshfield Clinic Research Foundation

๐Ÿ‡บ๐Ÿ‡ธ

Marshfield, Wisconsin, United States

MetroHealth Cancer Care Center at MetroHealth Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Cleveland, Ohio, United States

Lewistown Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Lewistown, Pennsylvania, United States

CCOP - Metro-Minnesota

๐Ÿ‡บ๐Ÿ‡ธ

St. Louis Park, Minnesota, United States

Penn State Cancer Institute at Milton S. Hershey Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Hershey, Pennsylvania, United States

CCOP - Hematology-Oncology Associates of Central New York

๐Ÿ‡บ๐Ÿ‡ธ

East Syracuse, New York, United States

CCOP - Northwest

๐Ÿ‡บ๐Ÿ‡ธ

Tacoma, Washington, United States

Green Bay Oncology, Limited - Sturgeon Bay

๐Ÿ‡บ๐Ÿ‡ธ

Sturgeon Bay, Wisconsin, United States

Pretoria Academic Hospital

๐Ÿ‡ฟ๐Ÿ‡ฆ

Pretoria, South Africa

Avera Cancer Institute

๐Ÿ‡บ๐Ÿ‡ธ

Sioux Falls, South Dakota, United States

Chester County Hospital

๐Ÿ‡บ๐Ÿ‡ธ

West Chester, Pennsylvania, United States

Dickinson County Healthcare System

๐Ÿ‡บ๐Ÿ‡ธ

Iron Mountain, Michigan, United States

Mayo Clinic Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Rochester, Minnesota, United States

Green Bay Oncology, Limited - Oconto Falls

๐Ÿ‡บ๐Ÿ‡ธ

Oconto Falls, Wisconsin, United States

Green Bay Oncology, Limited at St. Mary's Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Green Bay, Wisconsin, United States

St. Vincent's Comprehensive Cancer Center - Manhattan

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Mercy Cancer Center at Mercy Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Canton, Ohio, United States

CCOP - Wichita

๐Ÿ‡บ๐Ÿ‡ธ

Wichita, Kansas, United States

CCOP - Columbia River Oncology Program

๐Ÿ‡บ๐Ÿ‡ธ

Portland, Oregon, United States

CCOP - Greenville

๐Ÿ‡บ๐Ÿ‡ธ

Greenville, South Carolina, United States

Sanford Cancer Center at Sanford USD Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Sioux Falls, South Dakota, United States

Cedar Rapids Oncology Associates

๐Ÿ‡บ๐Ÿ‡ธ

Cedar Rapids, Iowa, United States

MBCCOP - Gulf Coast

๐Ÿ‡บ๐Ÿ‡ธ

Mobile, Alabama, United States

Mobile Infirmary Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Mobile, Alabama, United States

McCreery Cancer Center at Ottumwa Regional

๐Ÿ‡บ๐Ÿ‡ธ

Ottumwa, Iowa, United States

Mercy Medical Center - Sioux City

๐Ÿ‡บ๐Ÿ‡ธ

Sioux City, Iowa, United States

Beth Israel Deaconess Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Green Bay Oncology, Limited - Escanaba

๐Ÿ‡บ๐Ÿ‡ธ

Escanaba, Michigan, United States

Hunterdon Regional Cancer Center at Hunterdon Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Flemington, New Jersey, United States

Warren Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Phillipsburg, New Jersey, United States

CCOP - Southeast Cancer Control Consortium

๐Ÿ‡บ๐Ÿ‡ธ

Goldsboro, North Carolina, United States

Mount Nittany Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

State College, Pennsylvania, United States

Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Green Bay, Wisconsin, United States

St. Vincent Hospital Regional Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Green Bay, Wisconsin, United States

Medical X-Ray Center, PC

๐Ÿ‡บ๐Ÿ‡ธ

Sioux Falls, South Dakota, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath